Loxo reports Phase I RET inhibitor data

Loxo Oncology Inc. (NASDAQ:LOXO) reported response data from an open-label, international Phase I trial of its ret proto-oncogene (RET) inhibitor LOXO-292 to

Read the full 225 word article

User Sign In